종양학용 AI 시장 - 시장 규모, 점유율, 동향 분석 보고서 : 컴포넌트 유형별, 암 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

AI In Oncology Market Growth & Trends:

The global AI in oncology market size is expected to reach USD 19.17 billion by 2030, registering a CAGR of 28.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness significant growth owing to increasing prevalence of cancer among the global population, propelling the need to develop technologically advanced products to diagnose, treat, and analyze cancer. For instance, the International Agency for Research on Cancer (IARC) expects over 20.7 million new cases in 2023. Moreover, AI enables early detection, crucial for lowering mortality, especially through efficient screening programs.

Emerging markets are witnessing a rising prevalence of cancer due to various factors, including lifestyle changes & aging populations. The surge in cancer cases in these markets creates a demand for advanced technologies like AI in oncology to improve early detection, personalized treatment, and overall patient outcomes. For instance, in January 2024, India's first AI-Precision Oncology Centre (POC) was launched at Apollo Cancer Centre in Bengaluru. The POC will utilize the vast possibilities offered by AI to help oncologists, patients, and caregivers achieve the best possible results within a specified time frame.

AI is transforming the field of oncology by integrating vast datasets from multi-omics analyses with the latest developments in deep learning and high-performance computing techniques. AI applications are expanding to include new detection, screening, diagnosis, and classification approaches, cancer genomics characterization, tumor microenvironment analysis, prognostic and predictive biomarkers assessment, and strategies for follow-up and drug discovery. For instance, in October 2022, Model Medicines launched an oncology program focusing on identifying and developing therapeutics against two epigenetic and oncogenic targets, focusing on applications for solid and hematological malignancies.

The major players operating in the market are adopting strategies such as collaborations and partnerships with a major focus on development of newer products to aid in the early diagnosis of cancer, meet rising demand, and enhance research and development pipeline. For instance, in December 2022, AstraZeneca collaborated with Clinithink to launch an AI project for lung cancer. This project aims to detect lung cancer at an early stage to aid in the developing of effective treatment.

Furthermore, in November 2022, Google Health entered into a partnership with iCAD, Inc. for the improvement of breast cancer screening using the company's artificial intelligence technology. Additionally, a number of public and private organizations are focusing on funding and investment for R&D in AI-based oncology screening products. For instance, in March 2023, Artera received funding of USD 90 million for the launch and distribution of the ArteraAI Prostate Test, the first developed test for predicting therapy in localized prostate cancer.

AI In Oncology Market Report Highlights:

• Based on component type, the software solutions segment is anticipated to grow at the fastest CAGR over the forecast period, owing to increasing adoption of software solutions for a wide number of applications due to the better outcomes offered by this component
• Based on cancer type, the prostate cancer segment is anticipated to grow at the fastest CAGR over the forecast period in the market with rising prevalence amongst the population. Prostate cancer generally affects 13 out of every 100 men in the U.S., according to the data published by CDC
• Based on application type, the research and development segment is expected to grow at the lucrative CAGR over the forecast period. This is attributable to the widespread adoption and amalgamation of advanced AI-enabled algorithms in pharmaceutical companies
• Based on end-use, the hospitals dominated the market and registered the fastest growth owing to growing number of companies collaborating or introducing AI-powered cancer care solutions in hospitals
• North America dominated the market due to the availability of favorable government initiatives and digital infrastructure to provide digital solutions to patients

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Component outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. Application outlook
  • 2.2.4. End-use outlook
• 2.3. Competitive Landscape Snapshot

Chapter 3. AI In Oncology Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for early detection and classification of cancer
    • 3.2.1.1.1.Case study 1
    • 3.2.1.1.2.Case study 2
    • 3.2.1.2. Increasing prevalence of cancer
    • 3.2.1.2.1.Breast
    • 3.2.1.2.2.Barain & CNS
    • 3.2.1.2.3.Kidney
    • 3.2.1.2.4.Non-Hodgkin lymphoma
    • 3.2.1.2.5.Bladder
    • 3.2.1.2.6.Colon & rectum
    • 3.2.1.2.7.Prostate
    • 3.2.1.2.8.Case Study 3
    • 3.2.1.3. Rising adoption of precision medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High procurement and implementation cost
    • 3.2.2.2. Lack of skilled workforce
    • 3.2.2.3. High impact of regulations
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
• 3.4. Impact of COVID-19 on AI in Oncology Market

Chapter 4. AI In Oncology Market Segment Analysis, By Component, 2018 - 2030 (USD Million)

• 4.1. Definition and Scope
• 4.2. Component Segment Dashboard
• 4.3. Global AI In Oncology Market, by Component, 2018 to 2030
• 4.4. Software Solution
  • 4.4.1. Software Solution Market, 2018 - 2030 (USD Million)
• 4.5. Hardware
  • 4.5.1. Hardware Market, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. AI In Oncology Market Segment Analysis, By Cancer Type, 2018 - 2030 (USD Million)

• 5.1. Definition and Scope
• 5.2. Cancer Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.4. Breast Cancer
  • 5.4.1. Breast cancer market estimates and forecast, 2018 - 2030 (USD Million)
• 5.5. Lung Cancer
  • 5.5.1. Lung cancer market estimates and forecast, 2018 - 2030 (USD Million)
• 5.6. Prostate Cancer
  • 5.6.1. Prostate cancer market estimates and forecast, 2018 - 2030 (USD Million)
• 5.7. Colorectal Cancer
  • 5.7.1. Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Million)
• 5.8. Brain Tumor
  • 5.8.1. Brain tumor market estimates and forecast, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. AI In Oncology Market Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 6.1. Definition and Scope
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.4. Diagnostics (Pathology, Cancer Radiology)
  • 6.4.1. Diagnostics (pathology, cancer radiology) market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5. Radiation Therapy (Radiotherapy)
  • 6.5.1. Radiation therapy (radiotherapy) market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6. Research & Development (Drug Design, Development Process, etc.)
  • 6.6.1. Research & development (drug design, development process, etc.) market estimates and forecast, 2018 - 2030 (USD Million)
• 6.7. Chemotherapy
  • 6.7.1. Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• 6.8. Immunotherapy
  • 6.8.1. Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. AI In Oncology Market Segment Analysis, By End-use Type, 2018 - 2030 (USD Million)

• 7.1. Definitions and Scope
• 7.2. End-use Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.4. Hospitals
  • 7.4.1. Hospitals Market, 2018 - 2030 (USD Million)
• 7.5. Surgical Centers & Medical Institutes
  • 7.5.1. Surgical centers & medical institutes market estimates and forecast, 2018 - 2030 (USD Million)
• 7.6. Others (Pharmaceutical Companies, Research Institutes & Training Centers)
  • 7.6.1. Others (pharmaceutical companies, research institutes & training centers) market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. AI In Oncology Market Segment Analysis, By Region, By Component, By Cancer Type, By Application, By End-use, 2018 - 2030 (USD Million)

• 8.1. Definition & Scope
• 8.2. Regional Market Share Analysis, 2023 & 2030
• 8.3. Regional Market Dashboard
• 8.4. Regional Market Snapshot
• 8.5. SWOT Analysis
• 8.6. North America
  • 8.6.1. North America Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.6.2. U.S.
    • 8.6.2.1. Key Country Dynamic
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. U.S. Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.6.3. Canada
    • 8.6.3.1. Key Country Dynamic
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. Canada Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
• 8.7. Europe
  • 8.7.1. Europe Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.2. Germany
    • 8.7.2.1. Key Country Dynamic
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Germany Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.3. UK
    • 8.7.3.1. Key Country Dynamic
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. UK Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.4. France
    • 8.7.4.1. Key Country Dynamic
    • 8.7.4.2. Regulatory Framework
    • 8.7.4.3. Competitive Insights
    • 8.7.4.4. France Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.5. Italy
    • 8.7.5.1. Key Country Dynamic
    • 8.7.5.2. Regulatory Framework
    • 8.7.5.3. Competitive Insights
    • 8.7.5.4. Italy Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.6. Spain
    • 8.7.6.1. Key Country Dynamic
    • 8.7.6.2. Regulatory Framework
    • 8.7.6.3. Competitive Insights
    • 8.7.6.4. Spain Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.7. Denmark
    • 8.7.7.1. Key Country Dynamic
    • 8.7.7.2. Regulatory Framework
    • 8.7.7.3. Competitive Insights
    • 8.7.7.4. Denmark Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.8. Sweden
    • 8.7.8.1. Key Country Dynamic
    • 8.7.8.2. Regulatory Framework
    • 8.7.8.3. Competitive Insights
    • 8.7.8.4. Sweden Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.7.9. Norway
    • 8.7.9.1. Key Country Dynamic
    • 8.7.9.2. Regulatory Framework
    • 8.7.9.3. Competitive Insights
    • 8.7.9.4. Norway Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
• 8.8. Asia Pacific
  • 8.8.1. Asia Pacific Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.8.2. Japan
    • 8.8.2.1. Key Country Dynamic
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. Japan Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.8.3. China
    • 8.8.3.1. Key Country Dynamic
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. China Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.8.4. India
    • 8.8.4.1. Key Country Dynamic
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. India Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.8.5. South Korea
    • 8.8.5.1. Key Country Dynamic
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. South Korea Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.8.6. Australia
    • 8.8.6.1. Key Country Dynamic
    • 8.8.6.2. Regulatory Framework
    • 8.8.6.3. Competitive Insights
    • 8.8.6.4. Australia Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.8.7. Thailand
    • 8.8.7.1. Key Country Dynamic
    • 8.8.7.2. Regulatory Framework
    • 8.8.7.3. Competitive Insights
    • 8.8.7.4. Thailand Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
• 8.9. Latin America
  • 8.9.1. Latin America Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.9.2. Brazil
    • 8.9.2.1. Key Country Dynamic
    • 8.9.2.2. Regulatory Framework
    • 8.9.2.3. Competitive Insights
    • 8.9.2.4. Brazil Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.9.3. Mexico
    • 8.9.3.1. Key Country Dynamic
    • 8.9.3.2. Regulatory Framework
    • 8.9.3.3. Competitive Insights
    • 8.9.3.4. Mexico Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.9.4. Argentina
    • 8.9.4.1. Key Country Dynamic
    • 8.9.4.2. Regulatory Framework
    • 8.9.4.3. Competitive Insights
    • 8.9.4.4. Argentina Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
• 8.10. MEA
  • 8.10.1. MEA Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.10.2. South Africa
    • 8.10.2.1. Key Country Dynamic
    • 8.10.2.2. Regulatory Framework
    • 8.10.2.3. Competitive Insights
    • 8.10.2.4. South Africa Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.10.3. Saudi Arabia
    • 8.10.3.1. Key Country Dynamic
    • 8.10.3.2. Regulatory Framework
    • 8.10.3.3. Competitive Insights
    • 8.10.3.4. Saudi Arabia Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.10.4. UAE
    • 8.10.4.1. Key Country Dynamic
    • 8.10.4.2. Regulatory Framework
    • 8.10.4.3. Competitive Insights
    • 8.10.4.4. UAE Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)
  • 8.10.5. Kuwait
    • 8.10.5.1. Key Country Dynamic
    • 8.10.5.2. Regulatory Framework
    • 8.10.5.3. Competitive Insights
    • 8.10.5.4. Kuwait Healthcare AI in Oncology Market, 2018 - 2030 (USD Million)

Chapter 9. AI In Oncology Market - Competitive Analysis

• 9.1. Recent Developments & Impact Analysis, by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Profiles
  • 9.3.1. Azra AI
    • 9.3.1.1. Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. IBM
    • 9.3.2.1. Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Siemens Healthcare GmbH
    • 9.3.3.1. Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Intel Corporation
    • 9.3.4.1. Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. GE HealthCare
    • 9.3.5.1. Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. NVIDIA Corporation
    • 9.3.6.1. Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Digital Diagnostics Inc.
    • 9.3.7.1. Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. ConcertAI
    • 9.3.8.1. Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Median Technologies
    • 9.3.9.1. Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. PathAI
    • 9.3.10.1. Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives